DeepMed Research

Caspofungin

Generic Name: Caspofungin

Brand Names: Cancidas, Cancidas (previously Caspofungin MSD)

Drug Type: Small Molecule

Chemical Formula: C_₅₂H_₈₈N_₁₀O_₁₅

CAS Number: 162808-62-0

Unique Ingredient Identifier: F0XDI6ZL63

Background: Caspofungin (brand name Cancidas worldwide) is an antifungal drug and the first member of a new drug class called the echinocandins, as coined by Merck & Co., Inc. It is typically administered intravenously. It shows activity against infections with Aspergillus and Candida, and works by inhibiting β(1,3)-D-Glucan of the fungal cell wall.

Indication: For the treatment of esophageal candidiasis and invasive aspergillosis in patients who are refractory to or intolerant of other therapies.

Associated Conditions: Abscess, Intra-Abdominal, Candidemia, Esophageal Candidiasis, Fungal Infections, Invasive Aspergillosis, Oropharyngeal Candidiasis, Peritonitis, Pleural space infections

Clinical Trials

Open, Pharmacokinetic Study of Caspofungin Acetate in Immunocompromised Young Children With Febrile Neutropenia (0991-042)

Phase 2

Completed

Conditions: Fungal Infection

Interventions: Drug: caspofungin acetate

First Posted Date: 2006-02-15

Last Posted Date: 2017-02-23

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 16

Registration Number: NCT00292071

A Multicenter, Randomized, Double-Blind, Comparative Study to Evaluate the Safety, Tolerability, and Efficacy of 2 Dosing Regimens of an Antifungal Drug in the Treatment of Fungal Infections in Adults (0991-801)(COMPLETED)

Phase 3

Completed

Conditions: Invasive Candidiasis

Interventions: Drug: caspofungin acetate

First Posted Date: 2005-11-08

Last Posted Date: 2017-03-24

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 204

Registration Number: NCT00250432

Voriconazole and Caspofungin Acetate in Treating Invasive Fungal Infections in Patients With Weakened Immune Systems

Phase 2

Terminated

Conditions: Infection
Unspecified Adult Solid Tumor, Protocol Specific

Interventions: Drug: caspofungin acetate
Drug: voriconazole

First Posted Date: 2005-10-13

Last Posted Date: 2025-04-27

Lead Sponsor: OHSU Knight Cancer Institute

Target Recruit Count: 13

Registration Number: NCT00238355

Locations: 🇺🇸
OHSU Knight Cancer Institute, Portland, Oregon, United States

A Study of Caspofungin, Liposomal Amphotericin B or the Combination of Both for Patients After Stem-Cell Transplantation

Phase 2

Completed

Conditions: Hematopoietic Stem Cell Transplantation
Fungus Diseases

First Posted Date: 2005-09-07

Last Posted Date: 2008-01-16

Lead Sponsor: University Hospital Muenster

Target Recruit Count: 75

Registration Number: NCT00148148

Locations: 🇩🇪
KKS Münster University Hospital, Münster, NRW, Germany

Caspofungin Acetate in Treating Aspergillosis in Patients With Hematologic Cancer or in Patients Who Have Undergone a Stem Cell Transplant

Phase 2

Completed

Conditions: Cancer

First Posted Date: 2005-05-04

Last Posted Date: 2012-09-24

Lead Sponsor: European Organisation for Research and Treatment of Cancer - EORTC

Target Recruit Count: 171

Registration Number: NCT00110045

Locations: 🇸🇰
National Cancer Institute - Bratislava, Bratislava, Slovakia
🇨🇭
Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
🇩🇪
Medizinische Poliklinik, Universitaet Wuerzburg, Wuerzburg, Germany

and more 10 locations

Study of Micafungin in Patients With Invasive Candidiasis or Candidemia

Phase 3

Completed

Conditions: Candidiasis
Candidemia

Interventions: Drug: Micafungin
Drug: Caspofungin

First Posted Date: 2005-03-08

Last Posted Date: 2014-09-18

Lead Sponsor: Astellas Pharma Inc

Target Recruit Count: 611

Registration Number: NCT00105144

Caspofungin to Prevent Candidiasis in Adults in Hospital Intensive Care Units

Phase 3

Completed

Conditions: Candidiasis

First Posted Date: 2004-12-20

Last Posted Date: 2008-03-04

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 1200

Registration Number: NCT00099775

Locations: 🇺🇸
National Cancer Institute (NCI), Bethesda, Maryland, United States

Caspofungin Study for Fungal Infections in Adults in Critical Care Settings

Phase 3

Terminated

Conditions: Candidiasis

Interventions: Other: Placebo
Drug: Caspofungin

First Posted Date: 2004-11-03

Last Posted Date: 2014-12-05

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 1200

Registration Number: NCT00095316

Locations: 🇺🇸
Harbor UCLA Medical Center - Medicine - Infectious Diseases, Torrance, California, United States
🇺🇸
Loyola University - Emergency Facility, Maywood, Illinois, United States
🇺🇸
Cooper University Hospital - Infectious Diseases, Camden, New Jersey, United States

and more 23 locations

Documented Candida or Aspergillus Infections in Pediatric Patients (0991-043)

Phase 2

Completed

Conditions: Aspergillosis
Candidiasis

First Posted Date: 2004-05-13

Last Posted Date: 2017-02-23

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 50

Registration Number: NCT00082524

MK0991 Versus Amphotericin B for Empirical Therapy in Febrile, Neutropenic Pediatric Patients (0991-044)

Phase 2

Completed

Conditions: Neutropenia
Fever

First Posted Date: 2004-05-13

Last Posted Date: 2017-02-23

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 100

Registration Number: NCT00082537

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy